Citations 0
Letters to the Editor
July 2009

Questionable Efficacy for Naltrexone in Patients With Asp40

Author Affiliations

Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009

Arch Gen Psychiatry. 2009;66(7):796-797. doi:10.1001/archgenpsychiatry.2009.68

The article by Anton et al1 is less positive than it may appear. They find evidence that patients with the Asp40 allele are more likely to respond to naltrexone hydrochloride treatment for alcoholism, but only if they received medical management (MM) alone, not if they also received combined behavioral intervention (CBI). They explain this by saying that CBI

may have compensated for the placebo effect, thereby suppressing the chances of observing a main effect of naltrexone or a genetic interaction.1(p140)

First Page Preview View Large
First page PDF preview
First page PDF preview